AMA applauds congressional action on prescription drug transparency

Statement attributable to:
Barbara McAneny, M.D.
President, American Medical Association

“The AMA believes in transparency in prescription drug pricing, and we are pleased the House Ways & Means Committee moved the issue forward. Patients and their physicians want to be armed with more information, yet the current situation is opaque if not impenetrable. The committee is rightfully determined to expose factors that lead to high drug prices, and we look forward to continuing our efforts in that regard.”